Do corticosteroids cause rapid growth of glioblastoma?

Corticosteroids and Glioblastoma Growth

Corticosteroids are associated with inferior survival in glioblastoma patients, though the mechanism appears to be multifactorial rather than simply causing "rapid growth"—the evidence points to detrimental effects on treatment response, immune function, and overall mortality rather than direct tumor proliferation. 1

The Evidence on Steroids and Glioblastoma Outcomes

The most authoritative guidance comes from the 2021 EANO-ESMO guidelines, which explicitly state there is "strong evidence linking steroid use to inferior survival in glioblastoma." 1 This represents a significant shift in how we understand corticosteroid effects in brain tumors.

Key Clinical Findings:

Population-level data demonstrates clear survival detriment:

• Steroid use at 6 months post-diagnosis is independently associated with inferior survival, even after correcting for known prognostic factors 2
• Higher perioperative dexamethasone exposure (≥34 mg cumulative) is independently associated with increased mortality (HR: 1.40,95% CI: 1.07-1.83) 3
• This association persists regardless of other prognostic variables

The mechanism is NOT simple tumor growth acceleration: Recent experimental evidence shows the relationship is more nuanced:

• Daily dexamethasone can either promote OR suppress GBM growth depending on the time of day administered and the tumor's circadian clock gene expression 4
• The detrimental effects appear mediated through multiple pathways: induction of chemoresistance, suppression of antitumor immune responses, and modulation of DNA damage repair 5
• Steroid receptor coactivator-1 (SRC-1) has been identified as a key molecular mediator linking corticosteroid signaling to immune regulation and tumor recurrence 5

Clinical Management Algorithm

For symptomatic patients requiring steroids:

1. Use the minimum effective dose (often no more than 4 mg dexamethasone daily) 1, 6

   • Initial dosing: 4-16 mg/day for symptomatic tumor-associated edema 1
   • Higher doses (16 mg/day or more) only for severe symptoms with increased intracranial pressure 6

2. Taper as rapidly as clinically tolerated 1

   • Typical taper: over 2-4 weeks 1
   • Longer periods may be needed for patients on long-term steroids

3. Avoid prophylactic use 1

   • Do NOT use perioperatively in asymptomatic patients
   • Do NOT use during radiotherapy in asymptomatic patients
   • Prophylactic use is increasingly discouraged 1

For asymptomatic patients:

Do not initiate steroids. 1 Clinically asymptomatic patients seldom require anti-oedema treatment, and the survival detriment outweighs any theoretical benefit.

Critical Pitfalls to Avoid

1. Continuing steroids unnecessarily after symptom resolution - This is perhaps the most common error. Steroids should be tapered immediately once clinical benefit plateaus.

2. Using steroids during immunotherapy - Steroid use may be particularly detrimental in patients receiving immunotherapy approaches 1

3. Ignoring the 6-month landmark - Steroid use at 6 months post-diagnosis is a particularly strong negative prognostic indicator and should trigger aggressive tapering efforts 2

4. Failing to provide PJP prophylaxis - For steroid treatment >4 weeks, during RT/chemotherapy, or with lymphocyte count <1000/ml, use trimethoprim-sulfamethoxazole 1

The Nuance: Context-Dependent Effects

The relationship between steroids and glioblastoma is complex and context-dependent 5:

• Timing matters: Circadian rhythms influence whether dexamethasone promotes or suppresses tumor growth 4
• Dose matters: Higher cumulative doses show worse outcomes 3
• Treatment interactions matter: Particularly problematic when combined with radiotherapy and temozolomide 5

Alternative short-course approach: Recent evidence suggests short-course high-dose methylprednisolone (500 mg/day for 3 days postoperatively) may reduce complications without impairing survival 7, though this requires validation and represents a departure from standard dexamethasone-based regimens.

Bottom Line for Practice

Steroids don't make glioblastomas "grow quickly" in a simple sense, but they are definitively associated with worse survival outcomes. The mechanism involves treatment resistance, immune suppression, and microenvironmental changes rather than direct tumor proliferation. Use steroids only when symptomatic benefit is clear, at the lowest effective dose, and taper aggressively. The default position should be to avoid steroids unless neurological deficits require relief.